These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 26106466)

  • 1. Efficacy of Clarithromycin Containing Bismuth-Based Regimen as a Second-Line Therapy in Helicobacter Pylori Eradication.
    Mokhtare M; Agah S; Fakheri H; Hosseini V; Rezaei Hemami M; Ghafoori SM
    Middle East J Dig Dis; 2015 Apr; 7(2):75-81. PubMed ID: 26106466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of quadruple and triple Furazolidone containing regimens on eradication of helicobacter pylori.
    Mokhtare M; Hosseini V; Tirgar Fakheri H; Maleki I; Taghvaei T; Valizadeh SM; Sardarian H; Agah S; Khalilian A
    Med J Islam Repub Iran; 2015; 29():195. PubMed ID: 26157713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial.
    Fakheri H; Taghvaei T; Hosseini V; Bari Z
    Helicobacter; 2012 Feb; 17(1):43-8. PubMed ID: 22221615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure.
    Fakheri H; Bari Z; Sardarian H
    Helicobacter; 2012 Aug; 17(4):264-8. PubMed ID: 22759325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Clarithromycin-Containing Quadruple Therapy on Helicobacter Pylori Eradication after Nitroimidazole-Containing Quadruple Therapy Failure.
    Fakheri H; Bakhshi Z; Bari Z; Alhooei S
    Middle East J Dig Dis; 2016 Jan; 8(1):51-6. PubMed ID: 26933482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial.
    Lu B; Wang J; Li J; Liu L; Chen Y
    Helicobacter; 2019 Apr; 24(2):e12566. PubMed ID: 30780194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of fourteen-day sequential quadruple regimen: pantoprazole, bismuth, amoxicillin, metronidazole and or furazolidone as first-line therapy for eradication of
    Mansour-Ghanaei F; Samadi A; Joukar F; Tirgar Fakheri H; Hassanipour S; Ashoobi MT; Soltanipour S; Alizadeh A; Rezamand G; Fathalipour M
    EXCLI J; 2019; 18():644-652. PubMed ID: 31611747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial.
    Salmanroghani H; Mirvakili M; Baghbanian M; Salmanroghani R; Sanati G; Yazdian P
    PLoS One; 2018; 13(6):e0197096. PubMed ID: 29889843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Amoxicillin-Clarithromycin-Containing Bismuth Quadruple Therapy for Primary Eradication of Helicobacter pylori].
    Guo T; Wang Q; Wu X; Li XQ; Li Y; Fei GJ; Shu HJ; Li JN; Qian JM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2019 Feb; 41(1):75-79. PubMed ID: 30837046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
    Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
    BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial: efficacy and safety of azithromycin, ofloxacin, bismuth, and omeprazole compared with amoxicillin, clarithromycin, bismuth, and omeprazole as second-line therapy in patients with Helicobacter pylori infection.
    Minakari M; Davarpanah Jazi AH; Shavakhi A; Moghareabed N; Fatahi F
    Helicobacter; 2010 Apr; 15(2):154-9. PubMed ID: 20402818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
    Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimum duration of regimens for Helicobacter pylori eradication.
    Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
    Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
    Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure in Helicobacter pylori Eradication].
    Kwon S; Lee DH; Kang JB; Kim N; Park YS; Shin CM; Yoon H; Choi YJ
    Korean J Gastroenterol; 2018 Apr; 71(4):196-203. PubMed ID: 29684968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for
    Zhang YW; Hu WL; Cai Y; Zheng WF; Du Q; Kim JJ; Kao JY; Dai N; Si JM
    World J Gastroenterol; 2018 Oct; 24(40):4596-4605. PubMed ID: 30386109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial.
    Macías-García F; Bastón-Rey I; de la Iglesia-García D; Calviño-Suárez C; Nieto-García L; Domínguez-Muñoz JE
    Helicobacter; 2019 Feb; 24(1):e12546. PubMed ID: 30346636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seven-day quintuple regimen as a rescue therapy for Helicobacter pylori eradication.
    Mansour-Ghanaei F; Joukar F; Naghipour MR; Forouhari A; Saadat SM
    World J Gastroenterol; 2015 Jan; 21(2):661-6. PubMed ID: 25593496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
    Gisbert JP; Romano M; Gravina AG; Solís-Muñoz P; Bermejo F; Molina-Infante J; Castro-Fernández M; Ortuño J; Lucendo AJ; Herranz M; Modolell I; Del Castillo F; Gómez J; Barrio J; Velayos B; Gómez B; Domínguez JL; Miranda A; Martorano M; Algaba A; Pabón M; Angueira T; Fernández-Salazar L; Federico A; Marín AC; McNicholl AG
    Aliment Pharmacol Ther; 2015 Apr; 41(8):768-75. PubMed ID: 25703120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Quadruple regimens using domestically manufactured drugs in gastritis and duodenal ulcer patients for Helicobacter pylori eradication: a perspective, multicenter, randomized controlled trial].
    Gao W; Hu F; Cheng H; Wang H; Yang Y; Liang H; Zhang S; Meng F; Cui M; Wei H; Sheng J; An HJ; Jiang B; Chen Y; Li Y; Zuo X; Gong J; Zhao P; Dong L; Wang B; Jiang K; Zhang G; Li J; Zhao Y; Gao H; Yang L
    Zhonghua Yi Xue Za Zhi; 2016 Jan; 96(4):260-4. PubMed ID: 26879784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.